"{\n \"business_address\": \"1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803\", \n \"business_phone_no\": \"3024986700\", \n \"ceo\": \"Herv\\u00c3\\u00a9 Hoppenot\", \n \"cik\": \"0000879169\", \n \"company_url\": \"www.incyte.com\", \n \"employees\": 980, \n \"entity_legal_form\": \"CORPORATION\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"Building E336\", \n \"hq_address2\": \"Route 141 and Henry Clay Road\", \n \"hq_address_city\": \"Wilmington\", \n \"hq_address_postal_code\": \"19880\", \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"Delaware\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Biotechnology\", \n \"latest_filing_date\": \"2017-08-01\", \n \"legal_name\": \"INCYTE CORP\", \n \"lei\": \"549300Z4WN6JVZ3T4680\", \n \"long_description\": \"Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.\", \n \"mailing_address\": \"1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803\", \n \"name\": \"Incyte Corp\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000BNPSQ9\", \n   \"composite_figi_ticker\": \"INCY:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNAS\", \n   \"figi\": \"BBG000BNQ132\", \n   \"figi_exch_cntry\": \"UW\", \n   \"figi_ticker\": \"INCY:UW\", \n   \"figi_uniqueid\": \"EQ0012625500001000\", \n   \"last_crsp_adj_date\": \"2000-09-01\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNAS\", \n   \"primary_listing\": true, \n   \"security_name\": \"INCYTE CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"NASDAQ\", \n   \"ticker\": \"INCY\"\n  }, \n  {\n   \"composite_figi\": \"BBG008B6BKC6\", \n   \"composite_figi_ticker\": \"INCYEUR:XA\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XWBO\", \n   \"figi\": \"BBG008B6BKW4\", \n   \"figi_exch_cntry\": \"XA\", \n   \"figi_ticker\": \"INCYEUR:XA\", \n   \"figi_uniqueid\": \"EQ0000000041898292\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XWBO\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"WBO\", \n   \"ticker\": \"INCY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000BP5VH9\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"ICY:GF\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"ICY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000BP5XP6\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"ICY:GM\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"ICY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000BP5YC8\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"ICY:GB\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"ICY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000BP5VT6\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"ICY:GD\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"ICY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000BP5V34\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"ICY:GR\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"ICY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000BP5V34\", \n   \"composite_figi_ticker\": \"ICY:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000BP5X76\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"ICY:GS\", \n   \"figi_uniqueid\": \"EQ0012625500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"INCYTE CORP.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8Q6N2\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"ICY\"\n  }\n ], \n \"short_description\": \"Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.\", \n \"sic\": 8731, \n \"standardized_active\": true, \n \"stock_exchange\": \"NasdaqGS\", \n \"template\": \"industrial\", \n \"ticker\": \"INCY\"\n}"